Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43146 (
tumour suppressor
)
5,935
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In a number of human cancers genes capable of suppressing tumorigenicity have been identified and in some instances cloned. Successful isolation of such
tumour suppressor
genes has depended upon either the mapping of a locus which confers susceptibility to a specific tumour, or the finding of specific allele loss in the tumour cells of heterozygous individuals. In ovarian cancer it is known that a small proportion (approximately 5%) of tumours are due to inheritance (Lynch et al., 1989). However, as yet the locus responsible has not been mapped. The only incidence of allele loss in ovarian tumours reported is on the short arm of chromosome 11 using a
c-Ha-ras
I probe to detect an RFLP (Lee et al., 1989), and on 3p and 6 in a small number of cases (Ehlen & Dubeau (1990)). We describe here the results of analysis of 19 tumours for allele loss using a probe for a hypervariable locus on the long arm of chromosome 17. Approximately 77% (10/13) of tumours from informative patients showed complete or partial allele loss at this locus. Using a probe for the short arm of chromosome 17, 31% (4 of 13 informative patients) demonstrated allele loss at this position. These results suggest that possible involvement of more than one chromosomal locus in the development of ovarian cancer.
...
PMID:Allele loss from chromosome 17 in ovarian cancer. 225 Sep 14
The technique of somatic cell hybridization has established the phenomenon of tumour suppression and provided evidence for a genetic basis for suppression. Further refinements aimed at eventually identifying '
tumour suppressor
' genes include the use of monochromosome transfer via microcell hybridization. The application of this technique to the study of tumour suppression in tumorigenic HeLa cell x fibroblast hybrids, Wilms' tumour, retinoblastoma and osteosarcoma cells is described. The issue of whether tumour suppression involves a direct effect on expression of activated oncogenes is discussed. Transformation of normal human cells in culture by activated cellular oncogenes is an extremely rare event. This may be due to a relatively greater genomic stability of human cells compared to rodent cells. We describe the use of a spontaneously immortalized human keratinocyte cell line, HaCaT, for studies of the effects of introduction of activated
c-Ha-ras
oncogene into these cells, with particular reference to tumorigenic conversion.
...
PMID:A genetic basis for tumour suppression. 254 19
This investigation of oral squamous carcinoma in five individuals revealed that four of the patients were constitutionally heterozygous at the
c-Ha-ras
-1 locus and that the tumour from one patient had lost that heterozygosity. The loss of
c-Ha-ras
-1 alleles provides a useful marker for detecting deletions of genetic material located on the short arm of chromosome 11 (11p) and has been found in association with a number of malignant tumours but has not been previously described in carcinoma of the head and neck. The repeated association of 11p deletions with malignancies has led to the postulation of a recessive cancer gene or
tumour suppressor
gene at this location involved in carcinogenesis and tumour progression. This study indicates that such a mechanism may contribute to the development of oral squamous carcinoma.
...
PMID:Loss of Harvey ras heterozygosity in oral squamous carcinoma. 256 83